IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v15y2024i1d10.1038_s41467-024-47215-6.html
   My bibliography  Save this article

The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial

Author

Listed:
  • Elena Giudice

    (National Cancer Institute (NCI), National Institutes of Health (NIH)
    Università Cattolica del Sacro Cuore)

  • Tzu-Ting Huang

    (National Cancer Institute (NCI), National Institutes of Health (NIH))

  • Jayakumar R. Nair

    (National Cancer Institute (NCI), National Institutes of Health (NIH))

  • Grant Zurcher

    (National Cancer Institute (NCI), National Institutes of Health (NIH))

  • Ann McCoy

    (National Cancer Institute (NCI), National Institutes of Health (NIH))

  • Darryl Nousome

    (CCR, NCI, NIH)

  • Marc R. Radke

    (University of Washington)

  • Elizabeth M. Swisher

    (University of Washington)

  • Stanley Lipkowitz

    (National Cancer Institute (NCI), National Institutes of Health (NIH))

  • Kristen Ibanez

    (National Cancer Institute (NCI), National Institutes of Health (NIH))

  • Duncan Donohue

    (Computer and Statistical Services, Data Management Services, Inc. (a BRMI company), NCI)

  • Tyler Malys

    (Computer and Statistical Services, Data Management Services, Inc. (a BRMI company), NCI)

  • Min-Jung Lee

    (CCR, NCI, NIH)

  • Bernadette Redd

    (CCR, NCI, NIH)

  • Elliot Levy

    (CCR, NCI, NIH)

  • Shraddha Rastogi

    (CCR, NCI, NIH)

  • Nahoko Sato

    (CCR, NCI, NIH)

  • Jane B. Trepel

    (CCR, NCI, NIH)

  • Jung-Min Lee

    (National Cancer Institute (NCI), National Institutes of Health (NIH))

Abstract

The multi-cohort phase 2 trial NCT02203513 was designed to evaluate the clinical activity of the CHK1 inhibitor (CHK1i) prexasertib in patients with breast or ovarian cancer. Here we report the activity of CHK1i in platinum-resistant high-grade serous ovarian carcinoma (HGSOC) with measurable and biopsiable disease (cohort 5), or without biopsiable disease (cohort 6). The primary endpoint was objective response rate (ORR). Secondary outcomes were safety and progression-free survival (PFS). 49 heavily pretreated patients were enrolled (24 in cohort 5, 25 in cohort 6). Among the 39 RECISTv1.1-evaluable patients, ORR was 33.3% in cohort 5 and 28.6% in cohort 6. Primary endpoint was not evaluable due to early stop of the trial. The median PFS was 4 months in cohort 5 and 6 months in cohort 6. Toxicity was manageable. Translational research was an exploratory endpoint. Potential biomarkers were investigated using pre-treatment fresh biopsies and serial blood samples. Transcriptomic analysis revealed high levels of DNA replication-related genes (POLA1, POLE, GINS3) associated with lack of clinical benefit [defined post-hoc as PFS

Suggested Citation

  • Elena Giudice & Tzu-Ting Huang & Jayakumar R. Nair & Grant Zurcher & Ann McCoy & Darryl Nousome & Marc R. Radke & Elizabeth M. Swisher & Stanley Lipkowitz & Kristen Ibanez & Duncan Donohue & Tyler Mal, 2024. "The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial," Nature Communications, Nature, vol. 15(1), pages 1-14, December.
    • Handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-47215-6
    DOI: 10.1038/s41467-024-47215-6
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-024-47215-6
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-024-47215-6?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Silvia Domcke & Rileen Sinha & Douglas A. Levine & Chris Sander & Nikolaus Schultz, 2013. "Evaluating cell lines as tumour models by comparison of genomic profiles," Nature Communications, Nature, vol. 4(1), pages 1-10, October.
    2. Zhi-Xiong Zhou & Scott A. Lujan & Adam B. Burkholder & Marta A. Garbacz & Thomas A. Kunkel, 2019. "Roles for DNA polymerase δ in initiating and terminating leading strand DNA replication," Nature Communications, Nature, vol. 10(1), pages 1-10, December.
    3. Hyoung Kim & Haineng Xu & Erin George & Dorothy Hallberg & Sushil Kumar & Veena Jagannathan & Sergey Medvedev & Yasuto Kinose & Kyle Devins & Priyanka Verma & Kevin Ly & Yifan Wang & Roger A. Greenber, 2020. "Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models," Nature Communications, Nature, vol. 11(1), pages 1-16, December.
    4. Panagiotis A. Konstantinopoulos & Alexandre André B. A. Costa & Doga Gulhan & Elizabeth K. Lee & Su-Chun Cheng & Andrea E. Wahner Hendrickson & Bose Kochupurakkal & David L. Kolin & Elise C. Kohn & Jo, 2021. "A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer," Nature Communications, Nature, vol. 12(1), pages 1-8, December.
    5. Ludmil B. Alexandrov & Jaegil Kim & Nicholas J. Haradhvala & Mi Ni Huang & Alvin Wei Tian Ng & Yang Wu & Arnoud Boot & Kyle R. Covington & Dmitry A. Gordenin & Erik N. Bergstrom & S. M. Ashiqul Islam , 2020. "The repertoire of mutational signatures in human cancer," Nature, Nature, vol. 578(7793), pages 94-101, February.
    6. Diana Zatreanu & Helen M. R. Robinson & Omar Alkhatib & Marie Boursier & Harry Finch & Lerin Geo & Diego Grande & Vera Grinkevich & Robert A. Heald & Sophie Langdon & Jayesh Majithiya & Claire McWhirt, 2021. "Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance," Nature Communications, Nature, vol. 12(1), pages 1-15, December.
    7. Sameera Vipat & Dipika Gupta & Sagun Jonchhe & Hele Anderspuk & Eli Rothenberg & Tatiana N. Moiseeva, 2022. "The non-catalytic role of DNA polymerase epsilon in replication initiation in human cells," Nature Communications, Nature, vol. 13(1), pages 1-15, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Jun Dai & Shuyu Zheng & Matías M. Falco & Jie Bao & Johanna Eriksson & Sanna Pikkusaari & Sofia Forstén & Jing Jiang & Wenyu Wang & Luping Gao & Fernando Perez-Villatoro & Olli Dufva & Khalid Saeed & , 2024. "Tracing back primed resistance in cancer via sister cells," Nature Communications, Nature, vol. 15(1), pages 1-14, December.
    2. Taichi Igarashi & Marianne Mazevet & Takaaki Yasuhara & Kimiyoshi Yano & Akifumi Mochizuki & Makoto Nishino & Tatsuya Yoshida & Yukihiro Yoshida & Nobuhiko Takamatsu & Akihide Yoshimi & Kouya Shiraish, 2023. "An ATR-PrimPol pathway confers tolerance to oncogenic KRAS-induced and heterochromatin-associated replication stress," Nature Communications, Nature, vol. 14(1), pages 1-22, December.
    3. Pierre Murat & Guillaume Guilbaud & Julian E. Sale, 2024. "DNA replication initiation drives focal mutagenesis and rearrangements in human cancers," Nature Communications, Nature, vol. 15(1), pages 1-14, December.
    4. Chuxuan Li & Leora M. Maksoud & Yang Gao, 2025. "Structural basis of error-prone DNA synthesis by DNA polymerase θ," Nature Communications, Nature, vol. 16(1), pages 1-12, December.
    5. Teresa Maria Rosaria Noviello & Anna Maria Giacomo & Francesca Pia Caruso & Alessia Covre & Roberta Mortarini & Giovanni Scala & Maria Claudia Costa & Sandra Coral & Wolf H. Fridman & Catherine Sautès, 2023. "Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial," Nature Communications, Nature, vol. 14(1), pages 1-18, December.
    6. Oriol Pich & Iker Reyes-Salazar & Abel Gonzalez-Perez & Nuria Lopez-Bigas, 2022. "Discovering the drivers of clonal hematopoiesis," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
    7. Noah Sasa & Toshihiro Kishikawa & Masashi Mori & Rie Ito & Yumie Mizoro & Masami Suzuki & Hirotaka Eguchi & Hidenori Tanaka & Takahito Fukusumi & Motoyuki Suzuki & Yukinori Takenaka & Keisuke Nimura &, 2025. "Intratumor heterogeneity of HPV integration in HPV-associated head and neck cancer," Nature Communications, Nature, vol. 16(1), pages 1-22, December.
    8. Eline J. M. Bertrums & Jurrian K. Kanter & Lucca L. M. Derks & Mark Verheul & Laurianne Trabut & Markus J. Roosmalen & Henrik Hasle & Evangelia Antoniou & Dirk Reinhardt & Michael N. Dworzak & Nora Mü, 2024. "Selective pressures of platinum compounds shape the evolution of therapy-related myeloid neoplasms," Nature Communications, Nature, vol. 15(1), pages 1-16, December.
    9. Benjamin A. Nacev & Francisco Sanchez-Vega & Shaleigh A. Smith & Cristina R. Antonescu & Evan Rosenbaum & Hongyu Shi & Cerise Tang & Nicholas D. Socci & Satshil Rana & Rodrigo Gularte-Mérida & Ahmet Z, 2022. "Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets," Nature Communications, Nature, vol. 13(1), pages 1-15, December.
    10. Dillon S. McBride & Sofya K. Garushyants & John Franks & Andrew F. Magee & Steven H. Overend & Devra Huey & Amanda M. Williams & Seth A. Faith & Ahmed Kandeil & Sanja Trifkovic & Lance Miller & Trusha, 2023. "Accelerated evolution of SARS-CoV-2 in free-ranging white-tailed deer," Nature Communications, Nature, vol. 14(1), pages 1-15, December.
    11. Guidantonio Malagoli Tagliazucchi & Anna J. Wiecek & Eloise Withnell & Maria Secrier, 2023. "Genomic and microenvironmental heterogeneity shaping epithelial-to-mesenchymal trajectories in cancer," Nature Communications, Nature, vol. 14(1), pages 1-20, December.
    12. Ryan N. Ptashkin & Mark D. Ewalt & Gowtham Jayakumaran & Iwona Kiecka & Anita S. Bowman & JinJuan Yao & Jacklyn Casanova & Yun-Te David Lin & Kseniya Petrova-Drus & Abhinita S. Mohanty & Ruben Bacares, 2023. "Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing," Nature Communications, Nature, vol. 14(1), pages 1-16, December.
    13. Erik Elias & Arman Ardalan & Markus Lindberg & Susanne E. Reinsbach & Andreas Muth & Ola Nilsson & Yvonne Arvidsson & Erik Larsson, 2021. "Independent somatic evolution underlies clustered neuroendocrine tumors in the human small intestine," Nature Communications, Nature, vol. 12(1), pages 1-8, December.
    14. Luan Nguyen & Arne Hoeck & Edwin Cuppen, 2022. "Machine learning-based tissue of origin classification for cancer of unknown primary diagnostics using genome-wide mutation features," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
    15. Yoshitaka Sakamoto & Shuhei Miyake & Miho Oka & Akinori Kanai & Yosuke Kawai & Satoi Nagasawa & Yuichi Shiraishi & Katsushi Tokunaga & Takashi Kohno & Masahide Seki & Yutaka Suzuki & Ayako Suzuki, 2022. "Phasing analysis of lung cancer genomes using a long read sequencer," Nature Communications, Nature, vol. 13(1), pages 1-17, December.
    16. Xiaohang Yang & Xingyuan Hu & Jingjing Yin & Wenting Li & Yu Fu & Bin Yang & Junpeng Fan & Funian Lu & Tianyu Qin & Xiaoyan Kang & Xucui Zhuang & Fuxia Li & Rourou Xiao & Tingyan Shi & Kun Song & Jing, 2024. "Comprehensive multi-omics analysis reveals WEE1 as a synergistic lethal target with hyperthermia through CDK1 super-activation," Nature Communications, Nature, vol. 15(1), pages 1-23, December.
    17. Stefan Harjes & Harikrishnan M. Kurup & Amanda E. Rieffer & Maitsetseg Bayarjargal & Jana Filitcheva & Yongdong Su & Tracy K. Hale & Vyacheslav V. Filichev & Elena Harjes & Reuben S. Harris & Geoffrey, 2023. "Structure-guided inhibition of the cancer DNA-mutating enzyme APOBEC3A," Nature Communications, Nature, vol. 14(1), pages 1-13, December.
    18. Zhenhua Li & Huanbin Zhao & Wenjian Yang & Maud Maillard & Satoshi Yoshimura & Yu-Chih Hsiao & Xin Huang & Yoshihiro Gocho & Lauren Rowland & Anthony Brown & Landon Choi & Kristine R. Crews & Charles , 2025. "Molecular and pharmacological heterogeneity of ETV6::RUNX1 acute lymphoblastic leukemia," Nature Communications, Nature, vol. 16(1), pages 1-11, December.
    19. Minghao Li & Zicheng Zhang & Qianrong Wang & Yan Yi & Baosheng Li, 2022. "Integrated cohort of esophageal squamous cell cancer reveals genomic features underlying clinical characteristics," Nature Communications, Nature, vol. 13(1), pages 1-15, December.
    20. Wei Liu & Hongchao Cao & Jing Wang & Areeg Elmusrati & Bing Han & Wei Chen & Ping Zhou & Xiyao Li & Stephen Keysar & Antonio Jimeno & Cun-Yu Wang, 2024. "Histone-methyltransferase KMT2D deficiency impairs the Fanconi anemia/BRCA pathway upon glycolytic inhibition in squamous cell carcinoma," Nature Communications, Nature, vol. 15(1), pages 1-18, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-47215-6. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.